
New On The Block
- Tylenol and Listerine maker Kenvue Inc. (NYSE:KVUE) just named board member Kirk Perry as interim CEO, replacing Thibaut Mongon, as part of a strategic review to boost shareholder value. The company, once a part of Johnson & Johnson (NYSE:JNJ) and now a top-five favorite in billionaire Dan Loeb‘s portfolio, aims to simplify operations, possibly via divestitures. In other words, expect Kenvue to conduct the corporate equivalent of mouthwash: rinse and possibly spit out a few underperforming assets.